Immune Checkpoint Inhibitors in Gliomas.

Abstract:

PURPOSE OF REVIEW:Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise. RECENT FINDINGS:A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective treatment for gliomas. Biomarkers to identify characteristics of gliomas responsive to these therapies will be essential. These may include mismatch repair deficiency and high mutational load that might be germline, somatic, or acquired after therapy. Evidence on the use of immune checkpoint inhibitors in gliomas is evolving. Clinical trials are underway and results are eagerly awaited. Understanding the role of immune checkpoint inhibitors in combination with other treatment modalities for gliomas is crucial to the improvement of outcomes. The design and conduct of future clinical trials need to account for increasingly complex treatment options.

journal_name

Curr Oncol Rep

journal_title

Current oncology reports

authors

Tan AC,Heimberger AB,Khasraw M

doi

10.1007/s11912-017-0586-5

subject

Has Abstract

pub_date

2017-04-01 00:00:00

pages

23

issue

4

eissn

1523-3790

issn

1534-6269

pii

10.1007/s11912-017-0586-5

journal_volume

19

pub_type

杂志文章,评审
  • Fertility preservation and management of gonadal failure associated with lymphoma therapy.

    abstract::Treatment with cytotoxic chemotherapy and radiotherapy is associated with significant gonadal damage in men and women. The likelihood of gonadal failure following cytotoxic chemotherapy is dependent on the drug and dose, and in women there is also an effect of age at treatment. Irradiation of the testes or ovaries, ei...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0039-6

    authors: Howell SJ,Shalet SM

    更新日期:2002-09-01 00:00:00

  • Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development.

    abstract:PURPOSE OF REVIEW:The aim of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy. We focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies and future strategies. RECENT FINDINGS:The number of PD-1/PD-L1...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00928-5

    authors: Oliveira LJC,Gongora ABL,Jardim DLF

    更新日期:2020-06-12 00:00:00

  • Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?

    abstract::Peripheral T-cell lymphomas (PTCL) are rare and aggressive subtypes of non-Hodgkin's lymphoma. Compared to B cell lymphomas, the immunologic phenotype of PTCL portends a poorer prognosis, with the exception of anaplastic large cell lymphoma bearing the anaplastic lymphoma kinase protein. Patients with PTCL tend to pre...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-010-0125-0

    authors: Casulo C,Horwitz S

    更新日期:2010-11-01 00:00:00

  • Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

    abstract::The endothelins (ETs), which include ET-1, ET-2, ET-3, and their receptors ET-A and ET-B, play a major role in tumor growth, proliferation, apoptosis, angiogenesis, and bone metastasis. Atrasentan is a novel and selective inhibitor of ET-1 and ET-A. In vitro and in vivo data show that this oral agent is capable of inh...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-006-0045-1

    authors: Thakkar SG,Choueiri TK,Garcia JA

    更新日期:2006-03-01 00:00:00

  • Overview of electronic data sharing: why, how, and impact.

    abstract::Electronic data sharing is a critical, but underappreciated, requirement for modern medical informatics systems. This capability is facilitated by acquisition of structured clinical data, but optimized only if this data is stored and transmitted using standardized representations. Most electronic medical record and cl...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-012-0271-7

    authors: Jones RB,Reeves D,Martinez CS

    更新日期:2012-12-01 00:00:00

  • The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery.

    abstract:PURPOSE OF REVIEW:The American Society of Clinical Oncology (ASCO) palliative care recommendations have been updated into a full guideline. Symptom questionnaires-completed and reviewed with patients during care delivery-are poised to play a large role in this guideline because they provide a more comprehensive underst...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0571-z

    authors: Stover AM,Basch EM

    更新日期:2017-02-01 00:00:00

  • Human papillomavirus testing for primary cervical cancer screening.

    abstract::With our understanding of human papillomavirus (HPV) and cervical cancer, the availability of HPV testing, and the known limitations of cervical cytology, it is time to reassess cervical cancer screening technologies. This article reviews recent randomized trials comparing primary HPV testing with cervical cytology in...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0081-0

    authors: Runowicz CD,Garozzo S

    更新日期:2008-11-01 00:00:00

  • Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.

    abstract:PURPOSE OF REVIEW:Patients with cancer have an elevated risk of cardiovascular disease. This review describes the cardiovascular risks of different cancer therapies and the evidence for cardioprotective strategies. RECENT FINDINGS:Recent studies have provided additional support for the safety and efficacy of dexrazoxa...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00923-w

    authors: Upshaw JN

    更新日期:2020-06-20 00:00:00

  • Hepatitis c and lymphoma.

    abstract::Epidemiologic data presented in this review suggest the involvement of hepatitis C virus (HCV) in the patho- genesis of some histotypes of B-cell non-Hodgkin's lymphoma, in particular immunocytoma and lymphomas growing primarily in the liver and major salivary glands. Experimental data further support this hypothesis....

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0090-0

    authors: Silvestri F,Sperotto A,Fanin R

    更新日期:2000-03-01 00:00:00

  • Intensity-modulated radiation therapy for gastrointestinal tumors.

    abstract::Radiation plays an important role in the multimodal management of tumors of the gastrointestinal (GI) system. Intensity-modulated radiation therapy (IMRT) is a technological development that was introduced to limit the acute and late toxicities commonly associated with conventional radiation therapy. Numerous preclini...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-008-0032-9

    authors: Meyer JJ,Czito BG,Willett CG

    更新日期:2008-05-01 00:00:00

  • Contemporary management of tumors of the salivary glands.

    abstract::Management of tumors of the salivary glands requires a detailed understanding of the anatomy and pathologic processes affecting these glands. Salivary glands give rise to benign and malignant neoplasms and are affected by a variety of systemic diseases. CT remains the most common primary imaging study; magnetic resona...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-007-0011-6

    authors: Scianna JM,Petruzzelli GJ

    更新日期:2007-03-01 00:00:00

  • Particle Radiation Therapy for Gastrointestinal Cancers.

    abstract::Particle irradiation of cancerous disease has gained great traction in recent years. The ability for particle therapy centers to deliver radiation with a highly conformal dose distribution while maintaining minimal exit or excess dose delivered to normal tissue, coupled with various biological advantages particularly ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-016-0499-8

    authors: Shinoto M,Ebner DK,Yamada S

    更新日期:2016-03-01 00:00:00

  • Proton beam radiation therapy for head and neck malignancies.

    abstract::Proton beam radiation therapy (PBRT) has unique physical properties (e.g., Bragg Peak) that limit the amount of normal tissue irradiated in the head and neck region while maximizing the radiation delivered to the tumor. Radiation therapy is commonly used in both the primary and adjuvant setting for many head and neck ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-010-0089-0

    authors: Frank SJ,Selek U

    更新日期:2010-05-01 00:00:00

  • Prostate cancer screening.

    abstract::Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths in American men. Although the use of the prostate-specific antigen (PSA) test for prostate cancer screening since the 1990s has led to increased early diagnoses, the most recent studies are in conflict about the risks and b...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-010-0136-x

    authors: Cook ED,Nelson AC

    更新日期:2011-02-01 00:00:00

  • Prophylactic Measures During Induction for Acute Myeloid Leukemia.

    abstract:PURPOSE OF REVIEW:Improved management of infectious complications of acute myeloid leukemia (AML) has contributed substantially to the success of care over the past half century. An important approach to reducing infectious complications during the induction period of chemotherapy involves the use of prophylactic antib...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0574-9

    authors: McCarthy MW,Walsh TJ

    更新日期:2017-03-01 00:00:00

  • Preoperative and adjuvant treatment of localized rectal cancer.

    abstract::Although postoperative chemoradiation has a proven role in the treatment of stage II to III localized rectal cancer, recent trials have demonstrated the role of preoperative chemoradiation. A recent randomized trial has shown that preoperative chemoradiation yields higher rates of local control and sphincter preservat...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0016-6

    authors: Das P,Crane CH

    更新日期:2006-05-01 00:00:00

  • Targeting pediatric malignancies for T cell-mediated immune responses.

    abstract::Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, mo...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0108-7

    authors: Mackall CL,Helman LJ

    更新日期:2000-11-01 00:00:00

  • New approaches to lung cancer prevention.

    abstract::Lung cancer is the most common cause of cancer death worldwide. The overall 5-year survival rate remains disappointing at 14% or less. Several clinician- and community-based interventions show promise for reducing lung cancer incidence through prevention and smoking cessation. However, long-term heavy smokers retain a...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0060-9

    authors: McWilliams A,Lam S

    更新日期:2002-11-01 00:00:00

  • Recent advances in the management of gastrointestinal stromal tumors.

    abstract::Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the intestinal tract, are characterized by the expression of KIT, also known as CD117. Increasingly, primary tumors from novel sites are being described. The KIT gene is commonly mutated, causing constitutive activation of the protein and a...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0068-9

    authors: von Mehren M

    更新日期:2003-07-01 00:00:00

  • Current management of anal canal cancer.

    abstract::Squamous cell carcinoma of the anal canal historically has been treated with abdominoperineal resection, resulting in high rates of morbidity and local recurrence. Pioneering work led to the finding that radiation therapy (RT) combined with 5-fluorouracil (5-FU) and mitomycin results in high rates of local control and...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0027-1

    authors: Czito BG,Willett CG

    更新日期:2009-05-01 00:00:00

  • Single-Cell RNA-Sequencing in Glioma.

    abstract:PURPOSE OF REVIEW:In this review, we seek to summarize the literature concerning the use of single-cell RNA-sequencing for CNS gliomas. RECENT FINDINGS:Single-cell analysis has revealed complex tumor heterogeneity, subpopulations of proliferating stem-like cells and expanded our view of tumor microenvironment influenc...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0673-2

    authors: Johnson E,Dickerson KL,Connolly ID,Hayden Gephart M

    更新日期:2018-04-10 00:00:00

  • Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

    abstract::The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of me...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0065-2

    authors: Kounalakis N,Goydos JS

    更新日期:2005-09-01 00:00:00

  • New drug developments for patients with metastatic soft tissue sarcoma.

    abstract::For the subgroup of patients with inoperable gastrointestinal stromal tumors, progress has been made by the rapid development and approval of the targeted therapy imatinib mesylate. Small round cell sarcomas (SRCT), such as Ewing/primitive neuroectodermal tumor, desmoplastic SRCT, and rhabdomyosarcoma, are chemotherap...

    journal_title:Current oncology reports

    pub_type: 杂志文章,收录出版,评审

    doi:10.1007/s11912-005-0054-5

    authors: Hartmann JT,Patel S

    更新日期:2005-07-01 00:00:00

  • Early chemohormonal therapy in prostate cancer: preliminary data and randomized trials.

    abstract::Chemotherapy was traditionally perceived to be ineffective for prostate cancer and was only administered to patients with symptomatic hormone-refractory disease. Although previous reviews have confirmed this belief, recent studies have demonstrated significant antitumor activity with chemotherapy regimens. This articl...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0114-7

    authors: Petrylak DP

    更新日期:2003-05-01 00:00:00

  • Therapeutic advances for glioblastoma multiforme: current status and future prospects.

    abstract::Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three decades of laboratory and clinical research, a newly evolved chemoradiotherapy approach using the alkylating agent temozolomide during and after radiotherapy has res...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/BF02951428

    authors: Robins HI,Chang S,Butowski N,Mehta M

    更新日期:2007-01-01 00:00:00

  • Targeted Agents in Cervical Cancer: Beyond Bevacizumab.

    abstract::Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women throughout the world. Approximately two thirds of the patients are diagnosed with locally advanced cervical cancer, showing disappointing survival rates despite correct multidisciplinary management. Metastatic disease implies a poor pr...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0680-3

    authors: Marquina G,Manzano A,Casado A

    更新日期:2018-04-02 00:00:00

  • Current therapy for malignant mesothelioma.

    abstract::This review briefly summarizes the results of previous systemic (chemotherapy) and local (surgery and radiotherapy) treatment attempted to date for malignant mesothelioma. The prospects for newer modalities, ie molecular and biologic therapies, are also highlighted, including results of both preclinical and early clin...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0006-2

    authors: Smythe WR

    更新日期:2002-07-01 00:00:00

  • Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.

    abstract:PURPOSE REVIEW:B cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0694-x

    authors: Rhodes J,Mato A,Sharman JP

    更新日期:2018-04-11 00:00:00

  • The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

    abstract::The establishment of the Intergroup Rhabdomyosarcoma Study (IRS) Committee in 1972 by three extant American pediatric cooperative groups initiated five generations of studies in the multidisciplinary treatment of soft-tissue sarcomas. Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide (VA...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0012-z

    authors: Ruymann FB

    更新日期:2003-11-01 00:00:00

  • Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.

    abstract::Most patients with chronic lymphocytic leukemia are diagnosed at an early stage, when traditional staging systems fail to distinguish those with an aggressive disease course from those with an excellent prognosis. This failure underscores the need for better prognostic markers. Although many markers have been explored...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0048-9

    authors: Jain N,Lamanna N

    更新日期:2009-09-01 00:00:00